Annals of Oncology: Editor's Choice

You will find below links to the Annals of Oncology's 'Editor's Choice' articles - new category introduced in 2014 of articles selected by Jean-Charles Soria, Annals of Oncology Editor-in-Chief. These articles are open access to all!

Please note that although the articles are chosen for each new edition of the Annals of Oncology, the dates mentioned below are the first published online dates which may differ from the journal edition's publication date.

Filter

Date Title Topic
27 Dec 2016 Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the... Breast Cancer , Ovarian Cancer , Translational Research
28 Dec 2016 Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the... Drug Development
19 Jan 2017 High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients Translational Research , Pancreatic Cancer
24 Jan 2017 Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma Lymphomas , Translational Research
30 Jan 2017 Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cance... Anti-Cancer Agents & Biologic Therapy , Non-Small-Cell Lung Cancer, Metastatic
30 Jan 2017 PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected no... Non-Small-Cell Lung Cancer, Metastatic , Translational Research
07 Feb 2017 Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal Cancer Immunology and Immunotherapy , Anal Cancer
07 Feb 2017 Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX... Anti-Cancer Agents & Biologic Therapy , Non-Small-Cell Lung Cancer, Metastatic
07 Feb 2017 Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial Cancer Immunology and Immunotherapy , Non-Small-Cell Lung Cancer, Metastatic
13 Feb 2017 A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group Bioethics, Legal, and Economic Issues
22 Dec 2016 Validation and development of MTH1 inhibitors for treatment of cancer Anti-Cancer Agents & Biologic Therapy
22 Dec 2016 Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase... Cancer Immunology and Immunotherapy , Non-Small-Cell Lung Cancer, Metastatic
22 Dec 2016 Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized,... Cancer Immunology and Immunotherapy , Gastrointestinal Cancers
22 Dec 2016 ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chron... Lymphomas
26 Sep 2016 Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers Breast Cancer, Metastatic